rezvilutamide
jiangsu hengrui pharmaceuticals
[]
phiii shr3680, novel oral ari, + adt vs. bicalut + adt (control) in #1l high-volume #mhspc 30 mo f/u w/sig os and rpfs benefit w/novel ari vs control w/81.0% vs 67.9% orr and improved qol m over control &gt;g3 aes 20.7% vs 14.5% #asco22 nda pending in china 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope